
Update: TARDOC & ambulatory flat-fee tariffs 2027
Getting a new tariff code in Switzerland just became a competition for limited capacity
OAAT, the organisation that maintains TARDOC and the outpatient flat rates, has received more change requests than its office can handle. Its Board has now adopted criteria for deciding which requests get worked on for version 2028.
Here is what that means in practice.
Requests are ranked on three things:
→ Importance
→ Expected volume of impact
→ Technical feasibility
Top priority goes to requests that matter for security of supply, are needed to meet regulatory requirements, or support OAAT’s defined development priorities.Rejected outright: requests that conflict with tariff-setting principles, miss the formal minimum requirements, or ask for something existing structures already cover.
Deferred: requests that first need conceptual groundwork or additional data analysis.
Why this matters for medtech companies:
Since the new outpatient tariffs went live in 2026, many manufacturers are still working out how their technology is (or isn’t) reflected in them. If a procedure using your device is poorly remunerated, the physician has a financial reason not to use it, however strong your clinical evidence.
A change request or new code is one way to fix that. But a weak application now risks rejection or a long wait in the queue. And “already covered by existing structures” is a rejection reason you need to be ready to rebut with evidence.
The questions I’d be asking now:
• Do we know exactly how each product is coded and remunerated under TARDOC and the flat rates today, and where the gaps are?
• Can we credibly link our request to security of supply, regulatory requirements or OAAT’s development priorities?
• Do we have the cost and volume data to quantify impact, or would we be deferred for lack of it?
• Only OAAT’s five shareholders can submit at present, so which medical society or hospital association will carry our request to the FMH or H+ between 1st February and 30th April 2027?
For most device companies, the right first step is a structured gap assessment of the portfolio against the new tariff structures. Has your team already mapped its portfolio against the new tariffs, or is it still on the to-do list?
